Cas:328956-56-5 tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate manufacturer & supplier

We serve Chemical Name:tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate CAS:328956-56-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate

Chemical Name:tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate
CAS.NO:328956-56-5
Synonyms:gl-0164
Molecular Formula:C13H19NO3
Molecular Weight:237.29500
HS Code:2924299090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:314.8ºC at 760 mmHg
Density:1.132g/cm3
Index of Refraction:1.554
PSA:58.56000
Exact Mass:237.13600
LogP:3.15990

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like gl-0164 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,gl-0164 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,gl-0164 Use and application,gl-0164 technical grade,usp/ep/jp grade.


Related News: The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate manufacturer The insulin-only and bihormonal configurations may be helpful in diabetes. tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate supplier If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate vendor The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15. tert-butyl N-[2-(1-hydroxyethyl)phenyl]carbamate factory The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally.